Scie News
  • Sections
    • Health
    • Africa R&D
    • Biotech
    • In the Lab
    • First Opinion
  • Topics
    • Malaria/HIV/TB
    • Biotechnology
    • Cancer
    • Infectious Disease
    • Public Health
    • Agriculture
    • Environment
    • Governance
  • Multimedia
    • The Readout Loud
    • Science Happens
    • All Video
  • Newsletters
  • More
    • Most Popular
No Result
View All Result
Try Scie Plus
  • Sections
    • Health
    • Africa R&D
    • Biotech
    • In the Lab
    • First Opinion
  • Topics
    • Malaria/HIV/TB
    • Biotechnology
    • Cancer
    • Infectious Disease
    • Public Health
    • Agriculture
    • Environment
    • Governance
  • Multimedia
    • The Readout Loud
    • Science Happens
    • All Video
  • Newsletters
  • More
    • Most Popular
No Result
View All Result
Scie News
No Result
View All Result

Africa’s largest clinical trial on COVID-19 treatment launches in 13 countries

Esther Nakkazi by Esther Nakkazi
November 30, 2020
in Health
0
Africa promote appropriate agricultural technologies and innovations for agri-business resilience in COVID
0
SHARES
8
VIEWS
Share on FacebookShare on TwitterShare on LinkedinShare on WhatsappEmail a friend

DNDi and its partners will launch a 13 country clinical trial in Africa (including Uganda) for mild cases of COVID-19 – this will be the largest effort of its kind in Africa, and dovetails with a marked increase in cases in plenty of countries on the continent.

Treating mild cases is key in Africa because ICU capacity is not as strong as may be in other developed nations. All eyes are now turned to vaccines, but vaccines alone won’t be enough to stop the pandemic and save lives. Treatments are just as important.

 The goal of this trial, which is named ANTICOV is to identify treatments that prevent mild cases from progressing to severe forms of the disease – and thus prevent local health systems from being overwhelmed.

ANTICOV could be compared to SOLIDARITY, but while the SOLIDARITY trial deals focus on severe cases), ANTICOV focuses on mild cases.  It is an adaptive platform trial so researchers can add new treatments as the trial moves on or remove treatments deemed not to be effective as it moves forward.

 Hydroxychloroquine will be one of the drugs to be studied initially because there are no large multi-country studies yet about the efficacy of the drug for mild cases. HCQ remains the standard of care for COVID in 16 African countries, so this trial will provide key evidence to inform health policies and national guidelines.

The clinical trial will be carried out at 19 sites in 13 countries by the ANTICOV consortium, which includes 26 prominent African and global research and development (R&D) organizations, coordinated by the Drugs for Neglected Diseases initiative (DNDi), an international non-profit drug research and development (R&D) group with extensive partnerships in Africa.

“There is a need for large clinical trials in Africa for COVID-19 to answer research questions that are specific to an African context,” said Dr. John Nkengasong, Director of the Africa Centres for Disease Control and Prevention. “African countries have mounted an impressive response so far to COVID-19 and now is the time to prepare for future waves of the disease. We welcome the ANTICOV trial led by African doctors because it will help answer one of our most pressing questions: With limited intensive care facilities in Africa, can we treat people for COVID-19 earlier and stop our hospitals from being overwhelmed?”

ANTICOV is an open-label, randomized, comparative, ‘adaptive platform trial’ that will test the safety and efficacy of treatments in 2,000 to 3,000 mild-to-moderate COVID-19 patients in Burkina Faso, Cameroon, Côte d’Ivoire, the Democratic Republic of Congo (DRC), Equatorial Guinea, Ethiopia, Ghana, Guinea, Kenya, Mali, Mozambique, Sudan, and Uganda. ANTICOV aims to identify early treatments that can prevent the progression of COVID-19 to severe disease and potentially limit transmission.

“It is heartening to see so many African countries collaborate to get much-needed answers about our unique COVID-19 patient needs,” said Dr. Borna Nyaoke-Anoke, Senior Clinical Project Manager at DNDi, which is also the sponsor for clinical trials in the DRC, Kenya, and Sudan.

“Africa has for the most part avoided the large-scale mortality seen in other countries, but with lockdowns ending and borders opening, we need to be prepared. We need research here in Africa that will inform policies and test-and-treat strategies so that as clinicians we can give the best options to people with COVID-19.”

ANTICOV is an adaptive platform trial, an innovative type of clinical trial pioneered for cancer drugs that allow for several treatments to be simultaneously tested. Adaptive platform trials enable rapid decisions to be made, including adding, continuing, or stopping treatment arms based on an ongoing analysis of results.

Tags: #Covid-19#DNDi#hydroxychlorine
Previous Post

How Mauritius Fought the COVID-19 Pandemic and Won

Related Posts

How Mauritius Fought the COVID-19 Pandemic and Won
Health

How Mauritius Fought the COVID-19 Pandemic and Won

November 29, 2020
First medical training school to be opened in Sudan rebel-held territory next year
Health

First medical training school to be opened in Sudan rebel-held territory next year

November 23, 2020
New treatment approved for Malaria
Health

A rare blood group called Dante protects against malaria

September 23, 2020
Vouchers in private medical facilities improve maternal and newborn health
Health

Vouchers in private medical facilities improve maternal and newborn health

September 5, 2020
Industry Lobby the US Government to Make Africa Backslide on Plastics
Press Releases

Industry Lobby the US Government to Make Africa Backslide on Plastics

August 31, 2020
Uganda study finds bone loss doubled in young women initiating HIV drug and family planning
Health

Uganda study finds bone loss doubled in young women initiating HIV drug and family planning

August 31, 2020

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Most Popular

  • Facebook partners with African NGOs for Safer Internet day 2019

    Facebook partners with African NGOs for Safer Internet day 2019

    0 shares
    Share 0 Tweet 0
  • Kampala residents interest in Chinese Acupuncture therapy piqued

    0 shares
    Share 0 Tweet 0
  • Mbarara University innovation accelerates towards commercialisation

    0 shares
    Share 0 Tweet 0
  • Baylor-Uganda Leadership training improves healthcare outcomes

    0 shares
    Share 0 Tweet 0
  • Ugandan study to facilitate long-term research on risk factors for Non-Communicable Diseases 

    0 shares
    Share 0 Tweet 0
Scie News

© 2018 Scie News - Powered by Cyberspro.

Reporting on science from Africa

  • About Us
  • Advertise
  • Contact Us

Follow Us

No Result
View All Result

© 2018 Scie News - Powered by Cyberspro.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In